Biotron's decision to trial Bit225 with Dolutregravir, (ViiV's Tivicay), is interesting for several reasons.
Firstly, it is one of the few HIV/AIDS treatments that can be taken orally on a daily basis.
Secondly, it is also used as a 'post exposure prophylaxis'.
And finally,
"ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders...
"https://pharmaphorum.com/news/tivicay-approved-in-europe-in-new-dispersible-tablet-for-children-with-HIV/ (January 14, 2021)
Ann: COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS, page-69
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.011(39.3%) |
Mkt cap ! $15.33M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.5¢ | 1.7¢ | $374.7K | 18.97M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 1266038 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 689330 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |